HK1209635A1 - 包含 -氯- -氧代- -氧代- -嗎啉基 苯基 -噁唑烷- -基}甲基 -噻吩甲酰胺的藥物劑型 - Google Patents

包含 -氯- -氧代- -氧代- -嗎啉基 苯基 -噁唑烷- -基}甲基 -噻吩甲酰胺的藥物劑型

Info

Publication number
HK1209635A1
HK1209635A1 HK15110431.9A HK15110431A HK1209635A1 HK 1209635 A1 HK1209635 A1 HK 1209635A1 HK 15110431 A HK15110431 A HK 15110431A HK 1209635 A1 HK1209635 A1 HK 1209635A1
Authority
HK
Hong Kong
Prior art keywords
oxo
thiophenecarboxamide
oxazolidin
ylmethyl
morpholinyl
Prior art date
Application number
HK15110431.9A
Other languages
English (en)
Inventor
Klaus Benke
Heike Neumann
Wolfgang Mck
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209635(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1209635A1 publication Critical patent/HK1209635A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK15110431.9A 2012-07-03 2015-10-23 包含 -氯- -氧代- -氧代- -嗎啉基 苯基 -噁唑烷- -基}甲基 -噻吩甲酰胺的藥物劑型 HK1209635A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03
PCT/EP2013/063590 WO2014005934A1 (de) 2012-07-03 2013-06-28 Pharmazeutische darreichungsformen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophen-carboxamid

Publications (1)

Publication Number Publication Date
HK1209635A1 true HK1209635A1 (zh) 2016-04-08

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110431.9A HK1209635A1 (zh) 2012-07-03 2015-10-23 包含 -氯- -氧代- -氧代- -嗎啉基 苯基 -噁唑烷- -基}甲基 -噻吩甲酰胺的藥物劑型

Country Status (33)

Country Link
US (2) US20150125527A1 (zh)
EP (1) EP2869814B1 (zh)
JP (1) JP6166781B2 (zh)
KR (1) KR20150027284A (zh)
CN (1) CN104582684A (zh)
AP (1) AP3756A (zh)
AR (1) AR091621A1 (zh)
AU (1) AU2013286068A1 (zh)
BR (1) BR112015000043A2 (zh)
CA (1) CA2878123A1 (zh)
CL (1) CL2015000002A1 (zh)
CO (1) CO7240379A2 (zh)
CR (1) CR20150001A (zh)
CU (1) CU20140152A7 (zh)
DO (1) DOP2015000001A (zh)
EA (1) EA025016B1 (zh)
EC (1) ECSP14033581A (zh)
ES (1) ES2574627T3 (zh)
GT (1) GT201400306A (zh)
HK (1) HK1209635A1 (zh)
IL (1) IL236455A0 (zh)
IN (1) IN2014DN11066A (zh)
MA (1) MA37721B1 (zh)
MX (1) MX2015000053A (zh)
NZ (1) NZ703733A (zh)
PE (1) PE20150189A1 (zh)
PH (1) PH12014502833A1 (zh)
SG (1) SG11201408420YA (zh)
TN (1) TN2014000541A1 (zh)
TW (1) TW201414508A (zh)
UY (1) UY34856A (zh)
WO (1) WO2014005934A1 (zh)
ZA (1) ZA201500759B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
PT3377176T (pt) * 2016-02-23 2022-01-13 Morgandane Scient Llc Método de tratamento de pacientes aos quais foram coadministrados rivaroxabano e verapamil
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
AU2019311234A1 (en) * 2018-07-24 2021-02-04 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
CN112469398A (zh) * 2018-07-24 2021-03-09 拜耳公司 可口服给药并具有缓释作用的药物剂型
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
EP1083879B1 (en) * 1998-06-03 2004-09-29 Alza Corporation Devices for providing prolonged drug therapy
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
MX2011000277A (es) * 2008-07-08 2011-06-22 Ratiopharm Gmbh Composiciones farmaceuticas que comprenden 5-cloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-ti ofencarboxamida.
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
CN103037849A (zh) * 2010-06-22 2013-04-10 安成国际药业股份有限公司 具有减少的食物效应的控释组合物

Also Published As

Publication number Publication date
CN104582684A (zh) 2015-04-29
CA2878123A1 (en) 2014-01-09
IN2014DN11066A (zh) 2015-09-25
DOP2015000001A (es) 2015-07-15
ES2574627T3 (es) 2016-06-21
ZA201500759B (en) 2017-11-29
NZ703733A (en) 2016-12-23
SG11201408420YA (en) 2015-01-29
US20150125527A1 (en) 2015-05-07
MX2015000053A (es) 2015-04-10
MA37721B1 (fr) 2016-12-30
CR20150001A (es) 2015-02-06
WO2014005934A1 (de) 2014-01-09
CU20140152A7 (es) 2015-10-27
JP2015521648A (ja) 2015-07-30
PH12014502833A1 (en) 2015-02-02
BR112015000043A2 (pt) 2017-06-27
EA201590142A1 (ru) 2015-06-30
AR091621A1 (es) 2015-02-18
GT201400306A (es) 2015-08-25
MA37721A1 (fr) 2016-05-31
KR20150027284A (ko) 2015-03-11
AP3756A (en) 2016-07-31
TW201414508A (zh) 2014-04-16
AU2013286068A1 (en) 2015-01-29
AP2015008208A0 (en) 2015-01-31
TN2014000541A1 (en) 2016-03-30
JP6166781B2 (ja) 2017-07-19
EP2869814A1 (de) 2015-05-13
EA025016B1 (ru) 2016-11-30
US20140010876A1 (en) 2014-01-09
EP2869814B1 (de) 2016-04-06
UY34856A (es) 2013-12-31
ECSP14033581A (es) 2015-12-31
CO7240379A2 (es) 2015-04-17
CL2015000002A1 (es) 2015-05-29
PE20150189A1 (es) 2015-01-31
IL236455A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
HK1209635A1 (zh) 包含 -氯- -氧代- -氧代- -嗎啉基 苯基 -噁唑烷- -基}甲基 -噻吩甲酰胺的藥物劑型
HK1218850A1 (zh) 持續藥物遞送植入物
IL210483A0 (en) Pharmaceutical compositions comprising 5-chlooro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
IL235608A (en) Carriers for improved drug delivery
IL259824B (en) History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs
DK3639872T3 (da) Lægemiddeladministrationsanordning
DK2925272T3 (da) Lægemiddelopbevarings-, udleverings- og administrationssystem
DK2768559T3 (da) Lægemiddelindgivelsesanordning
HK1220978A1 (zh) 氨基磺酰基 -甲基- -噻唑- -基 -甲基- -吡啶基 苯基 乙酰胺甲磺酸鹽水合物
DK2740504T3 (da) Lægemiddelfremføringsanordning
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
EP2715359A4 (en) METHODS AND COMPOSITIONS FOR THE MONITORING AND DOSED ADMINISTRATION OF A THERAPEUTIC MEDICINE BY PHARMACO-KINETIC PROFILING ON PLACES OF CARE
DK2858986T3 (da) Piperidinderivater som gpr119-agonister
SMT201600421B (it) 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-one
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
EP2933290A4 (en) COMPOSITION FOR COMPLEX FORMATION, COMPLEX FORMED THEREFROM, AND COMPOSITION FOR ORAL ADMINISTRATION COMPRISING SAID COMPLEX
ITMI20130722A1 (it) Macchina di riempimento combinata, dotata di funzione di pesatura e di gestione del volume, per camere bianche
DK2785398T3 (da) Lægemiddeladministrationsanordning, som omfatter et betjeningshjælpemiddel
BR112013033052A2 (pt) formulações de entrega de fármaco
IL260578B (en) Pharmaceutical preparations containing 3,5-di-iodo-o-[3-iodo-4-(sulfoxy)phenyl]-l-tyrosine (t3s)
WO2014141067A3 (en) Process for the preparation of oxazolidinone derivatives
DK2983747T3 (da) Lægemiddelindgivelsesindretning
ITMI20130708A1 (it) Macchina di riempimento combinata, dotata di funzione di pesatura e di gestione del volume, per camere bianche
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
WO2012080184A3 (de) Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid